Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

According to an updated 5-year analysis of extended follow-up from the phase 3 POLARIX trial—presented during the 2024 American Society of Hematology Annual Meeting—polatuzumab vedotin plus R-CHP continues to demonstrate sustained and significant benefits for patients with previously untreated intermediate- and high-risk DLBCL. The 5-year PFS for the Pola-R-CHP arm was 63.1% vs 59.1% in the R-CHOP arm (HR 0.81; 95% CI: 0.652–0.996).